News and Events – Azura Ophthalmics

Press Releases

All

By Year

Apr. 20, 2023

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings

Jan. 17, 2023

Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference

Dec. 9, 2022

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Nov. 21, 2022

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Nov. 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Oct. 19, 2022

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

Sep. 28, 2022

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Sep. 21, 2022

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)

Sep. 7, 2022

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Sep. 7, 2021

Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board

Mar. 3, 2021

Azura Ophthalmics Announces Positive Topline Results from Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction

Dec. 21 2020

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort

Oct. 22, 2020

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

Oct. 10, 2017

Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease

Apr. 20, 2023

Jan. 17, 2023

Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference

Dec. 9, 2022

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Nov. 21, 2022

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Nov. 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Oct. 19, 2022

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

Sep. 28, 2022

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Sep. 21, 2022

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)

Sep. 7, 2022

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Sep. 7, 2021

Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board

Mar. 3, 2021

Azura Ophthalmics Announces Positive Topline Results from Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction

Events

Upcoming

Past

Nov. 29 – Dec. 1, 2022

Piper Sandler 34th Annual Healthcare Conference

Dec. 2-3, 2022

San Diego, CA

Ophthalmology Innovation Summit XII (OIS)

Jan. 9-12, 2023

San Francisco, CA

JP Morgan Healthcare Conference

Jan. 14-20, 2023

Hawaiian Eye and Retina 2023

Media

Oct. 22, 2020

Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases